文献速递糖尿病肥胖与代谢综合征

医院诊断抑郁或使用抗抑郁药对新诊断2型糖尿病治疗启动、依从性及HbA1c/LDL达标的影响

The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes.
PubMed 文献 · Diabetologia · 2020-10-19

该注册研究纳入2000–2016年丹麦中北部87,650例新诊断2型糖尿病个体,比较当前抗抑郁药治疗或既往医院诊断抑郁者与无抑郁治疗者在降糖/调脂治疗启动、依从性及HbA1c/LDL达标方面的差异。结果显示抗抑郁药治疗与降糖药启动及依从性、调脂药启动及依从性、LDL达标可能性增加相关,但与HbA1c达标无关;医院诊断抑郁者结果类似。

要点

  • 抗抑郁药治疗与新诊断2型糖尿病降糖药启动(HR 1.39)及依从性(OR 1.27)增加相关。
  • 抗抑郁药治疗与调脂药启动(HR 1.17)、依从性(OR 1.25)及LDL达标(OR 1.08)增加相关。
  • 抗抑郁药治疗与HbA1c达标无关(OR 0.99 [95% CI 0.93, 1.06])。

核心结论

  • 在新诊断2型糖尿病个体中,抗抑郁药治疗及抑郁与糖尿病治疗质量改善相关。

研究设计与样本

  • 基于注册的队列研究,纳入2000–2016年丹麦中北部首次HbA1c≥48 mmol/mol(6.5%)诊断的2型糖尿病个体共87,650例。
  • 暴露为糖尿病诊断前2年内精神病院诊断抑郁或当前接受抗抑郁药治疗,对照为无抑郁治疗或既往抑郁史者。
  • 采用回归分析调整潜在混杂因素,评估治疗启动、依从性(药物持有率>80%)及HbA1c/LDL达标。

主要发现

  • 0.9%(n=784)有医院诊断抑郁,11.4%(n=9963)当前接受抗抑郁药治疗。
  • 抗抑郁药治疗与降糖药启动(HR 1.39 [95% CI 1.34, 1.44])及依从性(OR 1.27 [95% CI 1.18, 1.36])增加相关。
  • 抗抑郁药治疗与调脂药启动(HR 1.17 [95% CI 1.11, 1.23])及依从性(OR 1.25 [95% CI 1.09, 1.43])增加相关。
  • 抗抑郁药治疗与LDL达标(OR 1.08 [95% CI 1.03, 1.14])增加相关,但与HbA1c达标无关(OR 0.99 [95% CI 0.93, 1.06])。
  • 医院诊断抑郁者的结果与抗抑郁药治疗者相似。

关键数值与推荐

  • 2型糖尿病诊断标准:首次HbA1c≥48 mmol/mol(6.5%)。
  • 依从性定义:药物持有率>80%。
  • HbA1c达标阈值:<53 mmol/mol(7%)。
  • LDL胆固醇达标阈值:<2.6 mmol/l。

临床怎么用

  • 对新诊断2型糖尿病合并抑郁或使用抗抑郁药者,可关注其降糖和调脂治疗启动与依从性可能较好。
  • 抗抑郁药治疗与LDL达标改善相关,但HbA1c达标未显示关联,仍需针对性管理血糖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to assess whether current antidepressant therapy or a history of hospital-diagnosed depression affects diabetes treatment initiation, adherence, and HbA1c and LDL-cholesterol target achievement. METHODS: In this register-based study, we included all individuals from Central and Northern Denmark with newly diagnosed type 2 diabetes, defined as a first-ever HbA1c measurement of ≥48 mmol/mol (6.5%), between 2000 and 2016. Individuals either diagnosed with depression at a psychiatric hospital in the 2 years prior to their diabetes diagnosis or currently receiving treatment with an antidepressant were compared with individuals with type 2 diabetes, but without depression treatment or previous history of depression. Outcome measures included initiation of glucose-lowering drugs and lipid-modifying agents, adherence to these medications (medication possession ratio >80%), and HbA1c (<53 mmol/mol [7%]) and LDL-cholesterol (<2.6 mmol/l) target achievement. The assessment of association between depression or antidepressant treatment and these outcomes was conducted using regression analyses with adjustment for potential confounders. RESULTS: We included a total of 87,650 individuals with first-ever HbA1c-diagnosed type 2 diabetes, of whom 0.9% (n = 784) had hospital-diagnosed depression and 11.4% (n = 9963) currently received antidepressant treatment. Compared with those without depression treatment, treatment with an antidepressant was associated with increased likelihood of glucose-lowering drug initiation (HR 1.39 [95% CI 1.34, 1.44]) and adherence (OR 1.27 [95% CI 1.18, 1.36]), lipid-modifying agent initiation (HR 1.17 [95% CI 1.11, 1.23]) and adherence (OR 1.25 [95% CI 1.09, 1.43]), and achievement of LDL (OR 1.08 [95% CI 1.03, 1.14]) but not HbA1c target (OR 0.99 [95% CI 0.93, 1.06]). The findings were similar for individuals who had hospital-diagnosed depression. CONCLUSIONS/INTERPRETATION: In individuals with newly diagnosed type 2 diabetes, antidepressant treatment and depression were associated with improved diabetes treatment quality. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rohde C, Knudsen JS, Schmitz N, et al. The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes. Diabetologia. 2020. PMID: 33073329. doi:10.1007/s00125-020-05303-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。